Daily allergic multimorbidity in rhinitis using mobile technology: A novel concept of the <scp>MASK</scp> study

Bousquet, Jean; Devillier, P.; Antó, JM; Bewick, Mike; Haahtela, Tari; Arnavielhe, Sylvie; Bedbrook, Anna; Murray, Ruth; Eerd, M. van; Fonseca, João; Almeida, Mário Morais de; Bom, Ana Todo; Menditto, Enrica; Passalacqua, Giovanni; Stellato, Cristiana; Triggiani, Massimo; Ventura, M. T.; Vezzani, G.; Annesi-Maesano, I.; Bourret, Rodolphe; Bossé, Isabelle; Caimmi, Davide; Cartier, Christine; Demoly, Pascal; Just, Jocelyne; Portejoie, F.; Siroux, Valérie; Viart, Frédéric; Bergmann, Karl‐Christian; Keil, Thomas; Klimek, Ludger; Mösges, Ralph; Pfaar, Oliver; Shamai, S.; Zuberbier, Torsten; Mullol, Joaquim; Valero, Antonio; Spranger, O.; Tomazic, Peter Valentin; Kowalski, Marcin; Kuna, Piotr; Kupczyk, Maciej; Raciborski, Filip; Samoliński, Bolesław; Toppila‐Salmi, Sanna; Valovirta, Erkka; Cruz, Álvaro Augusto; Sarquis-Serpa, F.; Silva, J. da; Stelmach, Rafaël; Larenas‐Linnemann, Désiree; González, Mayda; Cabanas, Marta; Kvedarienė, Violeta; Valiulis, Arūnas; Chavannes, Niels H.; Fokkens, Wytske J.; Ryan, Dermot; Sheikh, Aziz; Bachert, Claus; Hellings, Peter W.; Vandenplas, Olivier; Ballardini, Natalia; Kull, Inger; Melén, Erik; Westman, Marit; Wickman, Magnus; Bindslev‐Jensen, Carsten; Eller, Esben; Bosnic‐Anticevich, Sinthia; O’Hehir, Robyn E; Agache, Ioana; Bieber, Thomas; Casale, Thomas B.; Gemicioğlu, Bilun; Ivancevich, Juan Carlos; Vries, G. De; Sørensen, Martin V.; Yorgancıoğlu, Arzu; Laune, Daniel

doi:10.1111/all.13448

Cited by 80 publications

(93 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, it is possible that pre‐existing ocular disorders and a dupilumab–AD disease‐specific interaction may be responsible for this increased incidence in dupilumab‐treated patients with AD, particularly as conjunctivitis was not associated with dupilumab in trials in other type 2 diseases . Allergic conjunctivitis is a common comorbidity in asthma and allergic rhinitis, as well as in AD . Both lesional and nonlesional skin in AD are characterized by epithelial barrier dysfunction, including abnormalities in keratinocyte terminal differentiation, keratinocyte lipid production and tight junctions, which all contribute to increased transepidermal water loss .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Conjunctivitis in dupilumab clinical trials

et al. 2019

Self Cite

View full text Add to dashboard Cite

Summary Background Dupilumab blocks the shared receptor component for interleukin (IL)‐4 and IL‐13. It is approved in the U.S.A. for patients aged ≥ 12 years with moderate‐to‐severe atopic dermatitis (AD) uncontrolled by topical prescription medicines or who cannot use topical medicines, for patients in Japan whose AD is uncontrolled with existing therapies, for patients with moderate‐to‐severe AD in Europe who are candidates for systemic therapy and for patients aged ≥ 12 years for maintenance treatment of moderate‐to‐severe asthma uncontrolled with their current medicines. AD trials have reported increased incidence of conjunctivitis for dupilumab vs. placebo. Objectives To characterize further the occurrence and risk factors of conjunctivitis in dupilumab clinical trials. Methods We evaluated randomized placebo‐controlled trials of dupilumab in AD (n = 2629), asthma (n = 2876), chronic rhinosinusitis with nasal polyps (CRSwNP) (n = 60) and eosinophilic oesophagitis (EoE) (n = 47). Results In most AD trials, dupilumab‐treated patients had higher conjunctivitis incidence than placebo controls. Higher baseline AD severity and previous history of conjunctivitis were associated with increased conjunctivitis incidence. Conjunctivitis was mostly mild to moderate. Most cases recovered or resolved during the treatment period; two patients permanently discontinued dupilumab due to conjunctivitis or keratitis. Common treatments included ophthalmic corticosteroids, antibiotics, and antihistamines or mast cell stabilizers. Most cases were diagnosed by the investigators. In asthma and CRSwNP trials, the incidence of conjunctivitis was lower for both dupilumab and placebo than in AD trials; dupilumab did not increase the incidence compared with placebo. In the EoE trial, no patients had conjunctivitis. Conclusions Conjunctivitis was more frequent with dupilumab treatment in most AD trials. In dupilumab trials in other type 2 diseases, incidence of conjunctivitis was overall very low, and was similar for dupilumab and placebo. In AD, the incidence of conjunctivitis was associated with AD severity and prior history of conjunctivitis. The aetiology and treatment of conjunctivitis in dupilumab‐treated patients require further study. What's already known about this topic? Ocular disorders, including allergic conjunctivitis, are common in patients with atopic dermatitis (AD). In most dupilumab AD trials, dupilumab‐treated patients had higher conjunctivitis incidence than those receiving placebo. Most cases were mild to moderate and recovered or were recovering during study treatment; study treatment discontinuation due to conjunctivitis was rare. Conjunctivitis incidence was very low and similar for dupilumab and placebo in clinical trials in asthma, chronic rhinosinusitis with nasal polyps and eosinophilic oesophagitis. What does this study add? This analysis confirms and extends the results of the individual clinical trials. Baseline disease‐related factors, including AD severity, prior conjunctivitis history and certa...

show abstract

Section: Discussionmentioning

confidence: 99%

“…The incidence of ophthalmic complications increases with AD severity . Allergic conjunctivitis and other ocular surface disorders are also common comorbidities of other atopic disorders such as asthma and allergic rhinitis …”

mentioning

confidence: 99%

Conjunctivitis in dupilumab clinical trials

et al. 2019

Self Cite

View full text Add to dashboard Cite

show abstract

“…During a 2-year-period, the developers included data from over 4000 patients totalling over 30 000 days. Analysis of these data led to the description of a previously unrecognized pattern of uncontrolled multimorbidity [77,78].…”

Section: Big Datamentioning

confidence: 99%

Impact Of “eHealth” in Allergic Diseases and Allergic Patients

Alvarez-Perea¹,

Sánchez-García²,

R³

et al. 2019

J Investig Allergol Clin Immunol

View full text Add to dashboard Cite

The emergence of new technology enables allergists and patients to compile data and receive feedback regarding key symptoms, risk behavior, and/or management. The term "eHealth" refers to a diverse group of tools that use computerized technologies to improve both the efficacy and the efficiency of the health care industry. eHealth comprises a variety of technologies, as follows: mobile devices (mHealth) in medical care, including electronic diaries, wearable sensors, and adherence monitoring; health informatics (eg, electronic health records, computerized physician order entry, clinical decision support); telemedicine, which is the use of information and communication technologies for the management of diseases and medical education; social media platforms, and the analysis of information acquired through these platforms using "big data" technologies. In this review, we summarize the latest findings on the use of eHealth technology and the relevance of eHealth to allergic conditions. ResumenLa aparición de nuevas tecnologías conlleva para los alergólogos y los pacientes la posibilidad de recopilar datos y recibir información directa sobre los síntomas clave de las enfermedades, los comportamientos de riesgo y/o su manejo. El término "eHealth", o salud electrónica, se refiere a un grupo diverso de herramientas que utilizan tecnologías informáticas para mejorar la eficacia y la eficiencia de la industria de la salud. La "eHealth" comprende varias tecnologías, como el uso de dispositivos móviles aplicados a la salud ("mHealth"), incluyendo diarios electrónicos, sensores ponibles o monitorización de la adherencia terapéutica; la informática biomédica (por ejemplo, la historia clínica electrónica, la prescripción electrónica o los sistemas de ayuda a las decisiones clínicas); la telemedicina, que es el uso de las tecnologías de la información y la comunicación para el manejo de enfermedades y de educación sanitaria; las plataformas de redes sociales, y el análisis de la información adquirida a través de estas plataformas, usando técnicas de "big data" o inteligencia de datos. En esta revisión, resumimos la evidencia que rodea al uso de tecnologías "eHealth" y su relevancia para las enfermedades alérgicas.

show abstract

“…5,15 In Phase 3 ARIA focused on the implementation of emerging technologies for individualized and predictive medicine to develop ICPs for the management of AR and asthma by a multidisciplinary group centered around the patients (Mobile Airways Sentinel Network [MASK]). [16][17][18][19][20][21][22][23] The proposed ARIA Phase 4 is CM to provide an active and healthy lifestyle to patients with rhinitis and asthma across the lifecycle, irrespective of their sex or socioeconomic status, with the aim of reducing health and social inequities globally.…”

Section: Background the 4 Aria Phasesmentioning

confidence: 99%